錦勝集團(控股)(00794.HK)年度扭虧爲盈至260萬港元
格隆匯6月30日丨錦勝集團(控股)(00794.HK)公告,截至2025年3月31日止年度業績,集團轉虧爲盈,由上個財政年度淨虧損約1580萬港元轉爲本年度淨溢利約260萬港元。儘管經營環境嚴峻,憑藉集團在擴大收益來源方面的努力,集團於本年度得以維持其收益水平。集團本年度錄得收益約7.6億港元,同比輕微下降約0.5%。每股盈利0.68港仙。
毛利及毛利率均有所改善,主要歸因於集團透過一系列降本增效措施,有效維持營運效益、整合生產線及提升成本控制能力,抵銷因銷售組合的策略性調整、加重對紙板及半成品的生產比例而造成的利潤率下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.